PMID 25044103 2014 Phase II study of the GI-4000 KRAS vaccine after curative therapy in patients with stage I-III lung adenocarcinoma harboring a KRAS G12C, G12D, or G12V mutation.
PMID 23014527 2012 Molecular epidemiology of EGFR and KRAS mutations in 3,026 lung adenocarcinomas: higher susceptibility of women to smoking-related KRAS-mutant cancers.
rs121913529 in
KRAS gene and
Colorectal Neoplasms
PMID 21228335 2011 Efficacy according to biomarker status of cetuximab plus FOLFOX-4 as first-line treatment for metastatic colorectal cancer: the OPUS study.
PMID 23182985 2013 Mutant KRAS codon 12 and 13 alleles in patients with metastatic colorectal cancer: assessment as prognostic and predictive biomarkers of response to panitumumab.
PMID 20921465 2010 Randomized, phase III trial of panitumumab with infusional fluorouracil, leucovorin, and oxaliplatin (FOLFOX4) versus FOLFOX4 alone as first-line treatment in patients with previously untreated metastatic colorectal cancer: the PRIME study.
PMID 19114683 2009 Fluorouracil, leucovorin, and oxaliplatin with and without cetuximab in the first-line treatment of metastatic colorectal cancer.
PMID 18316791 2008 Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer.
PMID 25157968 2014 Prospective enterprise-level molecular genotyping of a cohort of cancer patients.
PMID 21398618 2011 Effect of simvastatin on cetuximab resistance in human colorectal cancer with KRAS mutations.
PMID 19679400 2009 Frequency and type of KRAS mutations in routine diagnostic analysis of metastatic colorectal cancer.
PMID 19881948 2009 BRAF(V600E) efficient transformation and induction of microsatellite instability versus KRAS(G12V) induction of senescence markers in human colon cancer cells.
PMID 20921462 2010 Randomized phase III study of panitumumab with fluorouracil, leucovorin, and irinotecan (FOLFIRI) compared with FOLFIRI alone as second-line treatment in patients with metastatic colorectal cancer.
PMID 16618717 2006 KRAS mutation status is predictive of response to cetuximab therapy in colorectal cancer.
PMID 16361624 2005 Randomized phase II trial of the clinical and biological effects of two dose levels of gefitinib in patients with recurrent colorectal adenocarcinoma.
rs121913529 in
KRAS gene and
Gastrointestinal Stromal Tumors
PMID 22282465 2012 KRAS and BRAF mutations predict primary resistance to imatinib in gastrointestinal stromal tumors.
PMID 19358724 2009 KRAS mutation analysis in ovarian samples using a high sensitivity biochip assay.
PMID 15696205 2005 KRAS mutations and primary resistance of lung adenocarcinomas to gefitinib or erlotinib.
PMID 17910045 2008 Mutations of FLT3, NRAS, KRAS, and PTPN11 are frequent and possibly mutually exclusive in high hyperdiploid childhood acute lymphoblastic leukemia.
PMID 17332249 2007 Spontaneous improvement of hematologic abnormalities in patients having juvenile myelomonocytic leukemia with specific RAS mutations.
PMID 17704260 2007 Cardio-facio-cutaneous and Noonan syndromes due to mutations in the RAS/MAPK signalling pathway: genotype-phenotype relationships and overlap with Costello syndrome.
PMID 21169357 2011 KRAS(G12V) enhances proliferation and initiates myelomonocytic differentiation in human stem/progenitor cells via intrinsic and extrinsic pathways.
PMID 19047918 2009 Correlation of clinical features with the mutational status of GM-CSF signaling pathway-related genes in juvenile myelomonocytic leukemia.
rs121913529 in
KRAS gene and
Leukemia, Myelocytic, Acute
PMID 3122217 1987 RAS gene mutations in acute and chronic myelocytic leukemias, chronic myeloproliferative disorders, and myelodysplastic syndromes.
PMID 2278970 1990 RAS gene mutations in childhood acute myeloid leukemia: a Pediatric Oncology Group study.
PMID 16434492 2006 Implications of NRAS mutations in AML: a study of 2502 patients.
PMID 22407852 2012 RAS mutations are frequent in FAB type M4 and M5 of acute myeloid leukemia, and related to late relapse: a study of the Japanese Childhood AML Cooperative Study Group.
rs121913529 in
KRAS gene and
Nevus sebaceous
PMID 23096712 2013 Whole-exome sequencing reveals somatic mutations in HRAS and KRAS, which cause nevus sebaceus.
rs121913529 in
KRAS gene and
Non-Small Cell Lung Carcinoma
PMID 21398618 2011 Effect of simvastatin on cetuximab resistance in human colorectal cancer with KRAS mutations.
PMID 17704260 2007 Cardio-facio-cutaneous and Noonan syndromes due to mutations in the RAS/MAPK signalling pathway: genotype-phenotype relationships and overlap with Costello syndrome.
PMID 22897852 2012 Therapeutic effect of γ-secretase inhibition in KrasG12V-driven non-small cell lung carcinoma by derepression of DUSP1 and inhibition of ERK.
PMID 15696205 2005 KRAS mutations and primary resistance of lung adenocarcinomas to gefitinib or erlotinib.
PMID 18794081 2008 Frequency and distinctive spectrum of KRAS mutations in never smokers with lung adenocarcinoma.
PMID 21169357 2011 KRAS(G12V) enhances proliferation and initiates myelomonocytic differentiation in human stem/progenitor cells via intrinsic and extrinsic pathways.
PMID 17332249 2007 Spontaneous improvement of hematologic abnormalities in patients having juvenile myelomonocytic leukemia with specific RAS mutations.
PMID 20609353 2010 A synthetic lethal interaction between K-Ras oncogenes and Cdk4 unveils a therapeutic strategy for non-small cell lung carcinoma.
PMID 12460918 2002 BRAF and RAS mutations in human lung cancer and melanoma.
PMID 19358724 2009 KRAS mutation analysis in ovarian samples using a high sensitivity biochip assay.
PMID 19029981 2008 Effective use of PI3K and MEK inhibitors to treat mutant Kras G12D and PIK3CA H1047R murine lung cancers.
PMID 19047918 2009 Correlation of clinical features with the mutational status of GM-CSF signaling pathway-related genes in juvenile myelomonocytic leukemia.
PMID 25157968 2014 Prospective enterprise-level molecular genotyping of a cohort of cancer patients.
PMID 22235099 2012 Mechanisms of resistance to crizotinib in patients with ALK gene rearranged non-small cell lung cancer.
PMID 17910045 2008 Mutations of FLT3, NRAS, KRAS, and PTPN11 are frequent and possibly mutually exclusive in high hyperdiploid childhood acute lymphoblastic leukemia.
PMID 26372703 2015 Prognostic value of the KRAS G12V mutation in 841 surgically resected Caucasian lung adenocarcinoma cases.
rs121913529 in
KRAS gene and
Stomach Carcinoma
PMID 3034404 1987 Activated c-Ha-ras oncogene with a guanine to thymine transversion at the twelfth codon in a human stomach cancer cell line.
PMID 14534542 2003 BRAF and KRAS mutations in stomach cancer.
PMID 7773929 1995 Clinicopathologic significance of the K-ras gene codon 12 point mutation in stomach cancer. An analysis of 140 cases.
rs121913529 in
KRAS gene and
Thyroid Neoplasm
PMID 19773371 2009 Beneficial effects of sorafenib on tumor progression, but not on radioiodine uptake, in patients with differentiated thyroid carcinoma.
PMID 23406027 2013 Selumetinib-enhanced radioiodine uptake in advanced thyroid cancer.
PMID 19255327 2009 Phase II trial of sorafenib in metastatic thyroid cancer.
PMID 21975775 2011 Epidermal growth factor receptor blockers for the treatment of ovarian cancer.
PMID 15696205 2005 KRAS mutations and primary resistance of lung adenocarcinomas to gefitinib or erlotinib.
PMID 17332249 2007 Spontaneous improvement of hematologic abnormalities in patients having juvenile myelomonocytic leukemia with specific RAS mutations.
PMID 17910045 2008 Mutations of FLT3, NRAS, KRAS, and PTPN11 are frequent and possibly mutually exclusive in high hyperdiploid childhood acute lymphoblastic leukemia.
PMID 19018267 2008 KRAS or BRAF mutation status is a useful predictor of sensitivity to MEK inhibition in ovarian cancer.
PMID 19047918 2009 Correlation of clinical features with the mutational status of GM-CSF signaling pathway-related genes in juvenile myelomonocytic leukemia.
PMID 19358724 2009 KRAS mutation analysis in ovarian samples using a high sensitivity biochip assay.